PharmaBlock Sciences Nanjing Inc Class A Cash Flow Conversion Efficiency
PharmaBlock Sciences Nanjing Inc Class A cash flow conversion efficiency. Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥83.36 Million ≈ $12.20 Million USD) by net assets (CN¥7.15 Billion ≈ $1.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
Cash flow conversion efficiency of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025. This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PharmaBlock Sciences Nanjing Inc Class A (300725) share price today for real-time trading data and today's change.
PharmaBlock Sciences Nanjing Inc Class A Cash Flow Conversion Ratio Explained
PharmaBlock Sciences Nanjing Inc Class A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaBlock Sciences Nanjing Inc Class A ranked by their cash flow conversion efficiency. Also see 300725 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nurix Therapeutics Inc
NASDAQ:NRIX
|
-0.154x |
|
Vietnam National Petroleum Group
VN:PLX
|
0.325x |
|
Xiamen Kingdomway Group Co
SHE:002626
|
0.040x |
|
SASA Polyester Sanayi AS
IS:SASA
|
0.052x |
|
GPS Participações e Empreendimentos S.A
SA:GGPS3
|
0.039x |
|
Changjiang Publishing & Media Co Ltd
SHG:600757
|
0.037x |
|
SLC Agrícola S.A
SA:SLCE3
|
-0.009x |
|
Photronics Inc
NASDAQ:PLAB
|
0.044x |
Annual Cash Flow Conversion Efficiency for PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
The table below shows the annual cash flow conversion efficiency of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025. Review PharmaBlock Sciences Nanjing Inc Class A (300725) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.30 Billion ≈ $921.91 Million |
CN¥667.36 Million ≈ $97.66 Million |
0.106x | +4.51% |
| 2024-12-31 | CN¥2.99 Billion ≈ $437.17 Million |
CN¥302.82 Million ≈ $44.31 Million |
0.101x | +16.30% |
| 2023-12-31 | CN¥2.83 Billion ≈ $414.45 Million |
CN¥246.84 Million ≈ $36.12 Million |
0.087x | -6.08% |
| 2022-12-31 | CN¥2.66 Billion ≈ $388.90 Million |
CN¥246.61 Million ≈ $36.09 Million |
0.093x | +2.44% |
| 2021-12-31 | CN¥2.63 Billion ≈ $384.52 Million |
CN¥238.03 Million ≈ $34.83 Million |
0.091x | -36.79% |
| 2020-12-31 | CN¥1.89 Billion ≈ $277.26 Million |
CN¥271.51 Million ≈ $39.73 Million |
0.143x | -16.44% |
| 2019-12-31 | CN¥740.87 Million ≈ $108.41 Million |
CN¥127.04 Million ≈ $18.59 Million |
0.171x | -35.79% |
| 2018-12-31 | CN¥599.73 Million ≈ $87.76 Million |
CN¥160.16 Million ≈ $23.44 Million |
0.267x | +146.14% |
| 2017-12-31 | CN¥503.59 Million ≈ $73.69 Million |
CN¥54.64 Million ≈ $8.00 Million |
0.108x | +21.17% |
| 2016-12-31 | CN¥254.15 Million ≈ $37.19 Million |
CN¥22.76 Million ≈ $3.33 Million |
0.090x | -52.32% |
| 2015-12-31 | CN¥146.56 Million ≈ $21.45 Million |
CN¥27.52 Million ≈ $4.03 Million |
0.188x | +37.48% |
| 2014-12-31 | CN¥87.18 Million ≈ $12.76 Million |
CN¥11.91 Million ≈ $1.74 Million |
0.137x | -47.68% |
| 2013-12-31 | CN¥70.16 Million ≈ $10.27 Million |
CN¥18.32 Million ≈ $2.68 Million |
0.261x | -- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the di… Read more